AIAtsushi Ishii

Atsushi Ishii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Atsushi Ishii has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ATAT1-dependent microtubule acetylation drives pancreatic tumorigenesis through DNMT1-mediated regulation of NDRG4

    by Julia Podgorski, Paola Cruz Flores, Monique R. Archuleta, Atsushi Ishii, Aaron Ramonett, Hannah R. Ortiz, Christopher Cartmell, Paul R. Langlais, Nathan A. Ellis, Karthikeyan Mythreye, et al.

    Microtubule (MT) acetylation is frequently elevated in cancer and associated with poor prognosis. Alpha-tubulin acetyltransferase 1 (ATAT1), the principal enzyme responsible for this modification, has therefore emerged as a potential therapeutic target. However, which cancer types depend on ATAT1 activity and are selectively vulnerable to its inhibition remains unclear. Here, using a phospho-specific marker of ATAT1 activity, we identify pancreatic ductal adenocarcinoma (PDAC) as an ATAT1-dependent malignancy. ATAT1 activity is elevated in human PDAC and genetically engineered mouse models, emerging during pancreatic intraepithelial neoplasia and persisting in a substantial subset of tumors. Genetic inactivation or pharmacologic inhibition of ATAT1 suppresses PDAC cell growth, reduces orthotopic tumor burden, and markedly inhibits tumor initiation in KPC mice without overt toxicity. Mechanistically, ATAT1-dependent MT acetylation sustains Akt signaling, resulting in inhibitory phosphorylation of GSK3β and stabilization of the DNA methyltransferase DNA methyltransferase 1 (DNMT1). Elevated DNMT1 promotes repression of tumor suppressor genes, including NDRG4, whereas inhibition of ATAT1 or DNMT1 restores NDRG4 expression and impairs tumor growth. Together, these findings identify a previously unrecognized ATAT1-Akt-GSK3β-DNMT1 signaling axis linking cytoskeletal acetylation to NDRG4 repression and reveal ATAT1 as a therapeutic vulnerability during the early stages of pancreatic tumorigenesis.

  • Open Access

    An intron retention-derived secreted Endoglin Isoform as a circulating biomarker in pancreatic ductal adenocarcinoma

    by Hannah R. Ortiz, Julia Podgorski, Monique R. Archuleta, Atsushi Ishii, Aaron Ramonett, Christopher Cartmell, Nathan A. Ellis, Paul R. Langlais, Karthikeyan Mythreye, Nadine Hempel, et al.

  • The effectiveness of intravenous benzodiazepine for status epilepticus in Dravet syndrome

    by Kenjiro Kikuchi, Shin-Ichiro Hamano, Ryuki Matsuura, Hazuki Nonoyama, Atsuro Daida, Yuko Hirata, Reiko Koichihara, Daishi Hirano, Atsushi Ishii, Shinichi Hirose


  • Open Access

    Comparative characterization of PCDH19 missense and truncating variants in PCDH19-related epilepsy

    by Mami Shibata, Atsushi Ishii, Ayako Goto, Shinichi Hirose

    Missense and truncating variants in protocadherin 19 (PCDH19) cause PCDH19-related epilepsy. In this study, we aimed to investigate variations in distributional characteristics and the clinical implications of variant type in PCDH19-related epilepsy. We comprehensively collected PCDH19 missense and truncating variants from the literature and by sequencing six exons and intron–exon boundaries of PCDH19 in our cohort. We investigated the distribution of each type of variant using the cumulative distribution function and tested for associations between variant types and phenotypes. The distribution of missense variants in patients was clearly different from that of healthy individuals and was uniform throughout the extracellular cadherin (EC) domain, which consisted of six highly conserved domains. Truncating variants showed two types of distributions: (1) located from EC domain 1 to EC domain 4, and (2) located from EC domain 5 to the cytoplasmic domain. Furthermore, we also found that later onset seizures and milder intellectual disability occurred in patients with truncating variants located from EC domain 5 to the cytoplasmic domain compared with those of patients with other variants. Our findings provide the first evidence of two types of truncating variants in the PCDH19 gene with regard to distribution and the resulting clinical phenotype.


  • Glucose transporter type 1 deficiency syndrome associated with autoantibodies to glutamate receptors

    by Hiroki Hoshino, Kazuko Takayama, Atsushi Ishii, Yukitoshi Takahashi, Hideaki Kanemura


  • Open Access

    Neuroanatomical Considerations for Optimizing Thalamic Deep Brain Stimulation in Tourette Syndrome

    by Takashi Morishita, Yuki Sakai, Hitoshi Iida, Saki Yoshimura, Atsushi Ishii, Shinsuke Fujioka, Saori C. Tanaka, Tooru Inoue

    Background: Deep brain stimulation (DBS) of the centromedian (CM) thalamic nucleus has reportedly been used to treat severe Tourette syndrome (TS) with promising outcomes; however, it remains unclear how DBS electrode position and stimulation parameters modulate the specific area and related networks. We aimed to evaluate the relationships between the anatomical location of stimulation fields and clinical responses including therapeutic and side effects. Methods: We collected data from eight TS patients treated with DBS. We evaluated the clinical outcomes using Yale Global Tic Severity Scale (YGTSS), Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and Hamilton Depression Rating Scale (HAM-D). The DBS lead location was evaluated in the normalised brain space using a 3-D atlas. The volume of tissue activated (VTA) was determined, and the associated normative connective analyses were performed to link the stimulation field with the therapeutic and side effects. Results: The mean follow-up period was 10.9 ± 3.9 months. All clinical scale showed significant significant improvement. While the VTA associated with therapeutic effects covers the CM and ventrolateral nuclei and showed association with motor networks, those associated with paraesthesia and dizziness were associated with stimulation of the ventralis caudalis and red nucleus, respectively. Depressed mood was associated with the spread of stimulation current to the mediodorsal nucleus and showed association with limbic networks. Conclusion: Our study addresses the importance of accurate implantation of DBS electrodes for obtaining standardised clinical outcomes and suggests that meticulous programming with careful monitoring of clinical symptoms may improve outcomes.


  • PRRT2 mutations in Japanese patients with benign infantile epilepsy and paroxysmal kinesigenic dyskinesia

    by Akihisa Okumura, Keiko Shimojima, Hirokazu Kurahashi, Shingo Numoto, Shino Shimada, Atsushi Ishii, Iori Ohmori, Satoru Takahashi, Tomonari Awaya, Tetsuo Kubota, et al.


  • Copy number variation analysis in 83 children with early-onset developmental and epileptic encephalopathy after targeted resequencing of a 109-epilepsy gene panel

    by Kyoko Hirabayashi, Daniela Tiaki Uehara, Hidetoshi Abe, Atsushi Ishii, Keiji Moriyama, Shinichi Hirose, Johji Inazawa

    Early-onset developmental and epileptic encephalopathy (DEE) is a group of devastating disorders that appear during the neonatal and infantile periods. Despite great progress in the discovery of genes leading to early-onset DEE, many cases with unexplained etiology remain. Furthermore, to date, the association of copy number variations (CNVs) with early-onset DEE has seldom been addressed. Here, we investigated the contribution of CNVs to epilepsy in a cohort of Japanese children with a variety of early-onset DEEs. Single nucleotide polymorphism (SNP) array analysis was performed for 83 cases that were previously negative for pathogenic single nucleotide variants (SNVs) in 109 genes known or suspected to cause epileptic seizures. Rare CNVs were detected in a total of 12 cases (14.4%), of which three cases (3.6%) involved clearly pathogenic CNVs and nine cases (10.8%) were CNVs of uncertain significance. The three pathogenic CNVs included two de novo heterozygous deletions involving known epileptic encephalopathy genes, such as GABRG2 and PCDH19, and one maternally inherited duplication encompassing MECP2. Our findings indicate rare CNVs are also relevant for the diagnosis of early-onset DEEs, highlighting the importance of not relying only on the investigation of SNVs/small indels at the risk of missing large deletions and duplications.


  • Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy

    by Ayako Goto, Atsushi Ishii, Mami Shibata, Yukiko Ihara, Edward C. Cooper, Shinichi Hirose

    Objective: Pathogenic variants of KCNQ2, which encode a potassium channel subunit, cause either benign (familial) neonatal epilepsy—B(F)NE)—or KCNQ2 encephalopathy (KCNQ2 DEE). We examined the characteristics of KCNQ2 variants.Methods: KCNQ2 pathogenic variants were collected from in‐house data and two large disease databases with their clinical phenotypes. Nonpathogenic KCNQ2 variants were collected from the Genome Aggregation Database (gnomAD). Pathogenicity of all variants was reevaluated with clinical information to exclude irrelevant variants. The cumulative distribution plots of B(F)NE, KCNQ2 DEE, and gnomAD KCNQ2 variants were compared. Several algorithms predicting genetic variant pathogenicity were evaluated.Results: A total of 259 individuals or pedigrees with 216 different pathogenic KCNQ2 variants and 2967 individuals with 247 different nonpathogenic variants were deemed eligible for the study. Compared to the distribution of nonpathogenic variants, B(F)NE and KCNQ2 DEE missense variants occurred in five and three specific KCNQ2 regions, respectively. Comparison between B(F)NE and KCNQ2 DEE sets showed that B(F)NE missense variants frequently localized to the intracellular domain between S2 and S3, whereas those of KCNQ2 DEE were more frequent in S6, and its adjacent pore domain, as well as in the intracellular domain between S6 and helix A. The scores of Protein Variation Effect Analyzer (PROVEAN) and Percent Accepted Mutation (PAM) 30 prediction algorithms were associated with phenotypes of the variant loci.Significance: Missense variants in the intracellular domain between S2 and S3 are likely to cause B(F)NE, whereas those in S6 and its adjacent regions are more likely to cause KCNQ2 DEE. With such regional specificities of variants, PAM30 is a helpful tool to examine the possibility that a novel KCNQ2 variant is a B(F)NE or KCNQ2 DEE variant in genetic analysis.


  • Different types of suppression-burst patterns in patients with epilepsy of infancy with migrating focal seizures (EIMFS)

    by Shinsaku Yoshitomi, Yukitoshi Takahashi, Katsumi Imai, Eriko Koshimizu, Satoko Miyatake, Mitsuko Nakashima, Hirotomo Saitsu, Naomichi Matsumoto, Mitsuhiro Kato, Takako Fujita, et al.